Top Markets
#1 Nesa Nesa +803.24%
#2 Cortex Cortex +69.09%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.77%
#4 QuantixAI QuantixAI +24.54%
#5 EXOD EXOD +22.78%
#6 Instadapp Instadapp +20.77%
#7 Pons Pons +20.18%
#8 PondCoin PondCoin +12.34%
#9 Cash Cat Cash Cat +12.29%
#10 Fartcoin Fartcoin +12.07%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
Mycenax Biotech Inc. Mycenax Biotech Inc.

Mycenax Biotech Inc.

4726
Rank in Stocks #19499
Mycenax Biotech Inc. specializes in the research, development, and... Mycenax Biotech Inc. specializes in the research, development, and manufacturing of biopharmaceutical products, leveraging both mammalian and microbial cell culture systems. Its market reach extends across Taiwan, Europe, Asia, and the United States. The company cultivates a diverse portfolio of advanced biological therapeutics and components. This includes monoclonal antibodies, bi-specific antibodies, Fc-fusion proteins, recombinant proteins, peptides, non-toxic protein conjugates, antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), in addition to plasmids and DNA vaccines. Beyond product innovation, Mycenax offers a comprehensive suite of process development solutions. These encompass the establishment of production cell lines, optimization of upstream and downstream processes, industrial scale-up, formulation science, and the creation of analytical methods. The firm also provides in-house analytical testing, Good Manufacturing Practice (GMP)-compliant manufacturing services for drug substances and finished products, and cell banking, all underpinned by its specialized manufacturing technologies. Established in 2001, Mycenax Biotech Inc. is headquartered in Zhubei, Taiwan.
Share Price
$0.77589628
Market Cap
$160.64M
Change (1 day)
0.00%
Change (1 year)
-37.43%
Country
TW
Trade Mycenax Biotech Inc. (4726)

Category

Healthcare
P/E ratio for Mycenax Biotech Inc. (4726)
P/E ratio as of 2026 TTM: 0
According to Mycenax Biotech Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Mycenax Biotech Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.